Quoin Pharmaceuticals Ltd ADR | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Quoin Pharmaceuticals Ltd ADR is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Netherton Syndrome in a number of indications (Approved).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| QRX003 | a number of indications | n/a | n/a | Public pipeline row |
| Netherton Syndrome (NS) | n/a | n/a | n/a | Public pipeline row |
| VLA-4 | treatment of Scleroderma | n/a | n/a | Public pipeline row |
| Product Candidate: QRX009 | Rare Vascular and Skin Malformations | n/a | n/a | Public pipeline row |
| QRX009 | n/a | n/a | n/a | Public pipeline row |
| Netherton Syndrome | n/a | n/a | Approved | Public pipeline row |
| Expanded Access Policy | n/a | n/a | Approved | Public pipeline row |
Estimated cash runway: Runway 6-12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| No public trial rows are loaded yet. | ||||
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.